ProCE Banner Activity

Experts Answer Frequently Asked Questions on the Management of Hodgkin Lymphoma

Clinical Thought
Do you have questions about the treatment of patients with advanced Hodgkin lymphoma? Read expert answers to key questions from the audience at a recent symposium on this topic.

Released: February 07, 2019

Expiration: February 06, 2020

Share

Faculty

Robert W. Chen

Robert W. Chen, MD

Associate Professor
Department of Hematology
City of Hope
Duarte, California

Joseph M. Connors

Joseph M. Connors, MD, FRCPC

Clinical Professor (emeritus)
Centre for Lymphoid Cancer
BC Cancer and the University of British Columbia
Vancouver, Canada

Andrew M. Evens

Andrew M. Evens, DO, MSc, FACP

Professor and Chief
Division of Hematology/Oncology
Tufts Medical Center
Boston, Massachusetts

Provided by

Provided by Postgraduate Institute for Medicine
ProCE Banner

Supporters

This activity is supported by educational grants from

Seagen

Takeda Oncology

Faculty Disclosure

Primary Author

Robert W. Chen, MD

Associate Professor
Department of Hematology
City of Hope
Duarte, California

Robert W. Chen, MD, has disclosed that he has received fees for non-CME/CE services from Merck and Seattle Genetics and consulting fees from Bristol-Myers Squibb, Merck, and Seattle Genetics.

Joseph M. Connors, MD, FRCPC

Clinical Professor (emeritus)
Centre for Lymphoid Cancer
BC Cancer and the University of British Columbia
Vancouver, Canada

Joseph M. Connors, MD, FRCPC, has disclosed that he has received consulting fees from Seattle Genetics.

Andrew M. Evens, DO, MSc, FACP

Professor and Chief
Division of Hematology/Oncology
Tufts Medical Center
Boston, Massachusetts

Andrew M. Evens, DO, MSc, FACP, has disclosed that he has received consulting fees from AbbVie, Acerta, Affimed, Bayer, Janssen, Pharmacyclics, and Seattle Genetics.